June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Uveitis Clinical Trials Analysis 2000-2015
Author Affiliations & Notes
  • Theodora Gkika
    University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
  • Shaista Giny
    University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
  • Andrej Kidess
    University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
  • Helen Palmer
    University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
  • Alastair K Denniston
    University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
  • Footnotes
    Commercial Relationships   Theodora Gkika, None; Shaista Giny, None; Andrej Kidess, None; Helen Palmer, None; Alastair Denniston, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 519. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Theodora Gkika, Shaista Giny, Andrej Kidess, Helen Palmer, Alastair K Denniston; Uveitis Clinical Trials Analysis 2000-2015. Invest. Ophthalmol. Vis. Sci. 2017;58(8):519.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyse the trends in the subject and design of clinical trials in uveitis from 2000-2015.

Methods : We conducted a systemic registry review of the NIH clinical trials registry (clinical trials.gov) for all trials categorised under uveitis . Data analysed included study design, type of uveitis included, source of funding; for interventional studies the phase, endpoint classification and type of intervention were also noted.

Results : A total of 216 studies were identified increasing from an average of 2 studies per year for 2000-2003 to 19 studies per year for 2012-2015. During the study period the proportion of studies that were interventional remained fairly constant at around 70%. The proportion of trials receiving industry funding increased from 14% (2000-2003) to 47% (2012-2015). Studies of intermediate/posterior/panuveitis (n=33) were almost twice as common as anterior uveitis (n=18), although most studies either specifed by syndrome (n=54) or did not restrict by anatomical subtype (n=127). Of the 157 interventional trials, the intervention was a drug in 146, a device in 6, and surgery/ other in 5. The number of phase 2/3 or later phase trials increased from <1/yr (2000-2003) to 7/yr (2012-2015), with randomised controlled trials increasing from <1/yr (2000-2003) to 5/yr (2012-2015).

Conclusions : There has been an increase in research investment in uveitis over the last 16 years, with greater engagement from industry and improved progression through the drug-development pipeline to later phase trials, and which is now providing benefit to patients through regulatory approval of therapeutics such as Ozurdex and adalimumab.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×